Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
10:19:52 EDT Fri 10 May 2024
Enter Symbol
or Name
USA
CA



Z:IBIO - IBIO INC - http://www.ibioinc.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
IBIO - Z2.01.80·1.900.21.80-0.08-4.316.824431.8375  1.84  1.8022.00  1.021410:02:19Mar 2715 min RT 2¢

Recent Trades - Last 10 of 43
Time ETExPriceChangeVolume
10:02:19Z1.80-0.081,000
10:00:05Z1.83-0.05100
10:00:05Z1.821-0.059397
10:00:05Z1.82-0.06200
10:00:05Z1.82-0.06100
10:00:05Z1.82-0.0631
09:59:53Z1.82-0.06100
09:59:38Z1.8312-0.04881
09:59:02Z1.86-0.0250
09:57:36Z1.82-0.06100

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2024-03-27 07:00U:IBIONews ReleaseiBio and AstralBio Announce Transformative AI drug discovery Collaboration to Rapidly Develop Novel Antibodies for Obesity and Cardiometabolic Diseases
2024-03-26 19:35U:IBIONews ReleaseiBio Announces $15.0 Million Private Placement
2024-02-26 07:45U:IBIONews ReleaseiBio Announces Sale of Preclinical PD-1 Agonist Antibody Program to Otsuka
2024-01-16 08:15U:IBIONews ReleaseiBio Announces Participation in 23rd Annual PepTalk Conference
2023-12-26 07:15U:IBIONews ReleaseiBio Amends and Extends Maturity of Credit Agreement
2023-12-05 08:00U:IBIONews ReleaseiBio, Inc. Announces Pricing of $4.5 Million Public Offering
2023-11-27 17:20U:IBIONews ReleaseiBio Announces Reverse Stock Split
2023-11-01 08:24U:IBIONews ReleaseiBio Further Expands Tech Stack with ShieldTx ¢ „ ¢; Enhances Immuno-Oncology ‚  Development Pipeline with Conditionally Activated MUC16xCD3 Bispecific
2023-10-10 08:00U:IBIONews ReleaseiBio to Highlight Technology for Advancing Discovery of Bispecifics at Festival of Biologics
2023-10-02 06:45U:IBIONews ReleaseiBio Explains Recent Filing of Registration Statement
2023-09-27 16:19U:IBIONews ReleaseiBio Announces Filing of 2023 Annual Report on SEC Form 10-K
2023-09-21 16:05U:IBIONews ReleaseiBio Announces Amendment to Credit Agreement with Woodforest
2023-08-14 16:15U:IBIONews ReleaseiBio Reports Triple Milestone: In Vivo Proof-of-Concept for Three Programs, a Transformative Step in Advancing its Immuno-Oncology Pre-Clinical Pipeline Towards Clinical Development
2023-06-27 08:00U:IBIONews ReleaseiBio Appoints Dr. Martin Brenner as CEO, Felipe Duran as CFO to Oversee Company ¢ € ™s Next Stage of Growth
2023-06-12 16:15U:IBIONews ReleaseiBio Forges Research Collaboration with the National Institutes of Health
2023-06-06 08:00U:IBIONews ReleaseiBio Expands Tech Stack with EngageTx ¢ „ ¢; Adds TROP-2 Bispecific to Development Pipeline